On November 30, 2021 Iterative Scopes, a pioneer in the development of precision-based gastrointestinal disease technologies, reported that it has CE marked its SKOUT medical device under the MDD (Directive 93/42/EEC) after successfully completing the assessment of the conformity of the device with the applicable MDD requirements in April 2021 (Press release, Iterative Scopes, NOV 30, 2021, View Source [SID1234596289]).1 This milestone marked the product’s first regulatory certification and will enable its distribution and marketing in Europe, a key step in Iterative Scopes’ global expansion plans.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SKOUT is an artificial intelligence (AI) driven medical device intended to detect potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening or surveillance.2
Using AI-enabled advanced computer vision technology, SKOUT recognizes suspicious tissue and provides real-time feedback to gastroenterologists, that draws their attention to areas of interest. According to clinical studies performed by Iterative Scopes, SKOUT has been demonstrated to confer an increase in Adenomas Per Colonoscopy when compared to historical controls,3 which can potentially have a significant impact to a patient’s risk for colorectal cancer.4
"The CE Mark is the first step of many in Iterative Scopes’ go to market plans to apply AI in gastroenterology," said Dan Wang, VP of Operations at Iterative Scopes. "SKOUT is our first product and targets colorectal cancer prevention. In addition, Iterative Scopes has developed a deep bench of other AI products which we have the internal strength and rigor in the regulatory domain to bring to market."
The ability to offer SKOUT to European gastroenterologists continues Iterative Scopes’ rapid growth this year as the company pursues its vision of applying proprietary, cutting-edge AI and computer-vision technologies to improving endoscopy.
A $30 million Series A financing that closed in August 2021 included a roster of top-tier investors and is supporting the company’s near-term goals of building its talent base and attracting major drug developers and other stakeholders that are key to its holistic approach to transforming the GI space.
Iterative Scopes was founded in 2017 as a spin out of the Massachusetts Institute of Technology (MIT) by Jonathan Ng, MBBS a physician entrepreneur, who developed the company’s foundational concepts while he was at MIT and Harvard.